Amgen has deployed “500 to 1,000” reps in support of Prolia (denosumab), a biologic osteoporosis treatment that received FDA approval on June 1. The drug was approved in the European Union on May 28.
Ethicon Endo-Surgery, CBS HealthWatch partner for colon disease awareness
Johnson & Johnson’s Ethicon Endo-Surgery partnered with CBS HealthWatch and the American Society of Colon and Rectal Surgeons for a web event broadcast live from EES’s booth at the Society’s ongoing annual meeting.
Covidien launches two pain drugs with fresh sales forces
Covidien announced the launch of two branded pain drugs — Exalgo and Pennsaid — and hired around 250 reps to support the products. Professional ads are in the works for May.
Novo reps to spotlight weight loss for Victoza launch
The FDA approved 17 new molecular entities and seven biologics license applications in 2009. That’s a substantial improvement in large molecule approvals — the agency granted just three BLAs last year — and a slight downturn in new chemical compounds, from last year’s 21 NMEs.
AstraZeneca airs “consuming” consumer for Seroquel XR bipolar depression
AstraZeneca launched the first consumer TV and print ads for Seroquel XR for bipolar depression, playing on the all-consuming way in which patients experience the disease.
King’s launch of Embeda, a pain drug containing morphine, demonstrates that even supposedly abuse-resistant narcotic products need to take a careful approach in their marketing.
Prevacid OTC switch gets $200 million launch effort
Human Genome Sciences and GlaxoSmithKline said online communication will play a key role in the upcoming launch of lupus drug Benlysta. The companies are considering various web channels, from advocacy groups to social media.